Drug Topics

NOVEMBER 3, 2023

During a session at AMCP Nexus, presenters discussed the delicate balance between cost and innovation as it relates to forthcoming oncology treatments.

98

98

Fierce Pharma

MARCH 20, 2024

After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy (MLD) in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have | After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S.,

FDA 104

FDA 104

Fierce Pharma

MAY 14, 2024

regulators last month, Eisai and Biogen’s effort to deploy a more convenient version of their Alzheimer’s disease drug Leqembi appears to be back on track. After suffering a setback with U.S.

FDA 89

FDA 89

The Checkup by Singlecare

NOVEMBER 22, 2023

Skin tags are one of those things you probably don’t think about until you spot one. At first glance, you may fear it’s a symptom of psoriasis , eczema , HPV warts, or skin cancer —but skin tags are common, noncancerous, and essentially harmless. Read on to see what experts say about the following 13 home remedies for skin tags.

FDA 115

FDA 115

Pharmaceutical Technology

OCTOBER 9, 2023

The FDA decision follows a similar designation for the vaccine UV1 against malignant melanoma in December 2021.

Vaccines 52

Vaccines FDA 52

Pharmaceutical Technology

JANUARY 31, 2024

The FDA has granted an orphan drug designation to Revolo’s ‘1104, with plans for a Phase IIb study later this year.

FDA 52

FDA 52

The Checkup by Singlecare

FEBRUARY 17, 2024

Skin tags , also called acrochordons, are harmless growths that can occur anywhere on your body but tend to develop in more friction-heavy areas like the armpit, the neck along the seat belt line where clothes and jewelry touch, under the breasts, in the groin, or on the face—specifically, the eyelid. What causes skin tags on eyelids?

Medical Schools 80

Medical Schools FDA 80

Pharmaceutical Technology

FEBRUARY 22, 2024

Harmony is advancing pitolisant into a Phase III clinical trial that is expected to start in Q1 2024.

52

52

Pharmacy Times

APRIL 17, 2023

Although payers have become somewhat accustomed to the high cost of specialty drugs, the price tags for gene therapies are causing “sticker shock.”

123

123

Pharmaceutical Technology

OCTOBER 17, 2023

The Netherlands-based company’s treatment has been awarded the designation by the US FDA following a successful Phase I trial.

FDA 52

FDA 52

Pharmaceutical Technology

NOVEMBER 20, 2023

NeoImmuneTech is developing NT-17, an IL-7 treatment, to promote rapid T-cell recovery in patients with acute radiation syndrome.

52

52

STAT

APRIL 12, 2024

In response to controversy, a group of Colorado lawmakers is abandoning a bill that would have required a new state board — which is chartered with setting caps for the cost of medicines — to create exemptions for rare disease drugs. Continue to STAT+ to read the full story…

100

100

Pharmaceutical Technology

APRIL 25, 2024

A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.

52

52

Pharmaceutical Technology

AUGUST 1, 2023

Vepdegestrant was awarded the Innovation Passport designation for treating advanced or metastatic breast cancer.

52

52

STAT

JANUARY 30, 2024

In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. government on Tuesday announced a long-awaited “access model” designed to blunt the cost that state Medicaid programs would pay for these curative treatments. million and $3.1

124

124

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 64

FDA Immunization 64

The People's Pharmacy

JUNE 5, 2023

People often want to know how to make skin tags go away. Here is one person’s story on how to avoid skin tags. Lowering Blood Sugar Helped Reader Avoid Skin Tags: Q. I had a number of skin tags on my neck. Then I noticed that the skin tags had totally disappeared. How Can You Avoid Skin Tags?

65

65

PharmaShots

JUNE 13, 2023

Eisai's and Merck Announces EU's Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular Carcinoma Published: 23 Aug,2018 | Tags: Eisai, Merck, Approval, Lenvima, HCC, 2. Pfizer to co-promote Exact Sciences Cologuard Published: 22 Aug,2018 | Tags: Exact, Pfizer, Agreement, Promote, Cologuard 7.

Labelling 52

Labelling FDA 52

Pharma Tutor

OCTOBER 13, 2022

DRUG REPURPOSING : A REVIEW. Read more about DRUG REPURPOSING : A REVIEW Log in or register to post comments Read more about DRUG REPURPOSING : A REVIEW Log in or register to post comments Email : charmiagarwal823@gmail.com. Thu, 10/13/2022 - 15:56. Review Articles.

95

95

STAT

NOVEMBER 16, 2023

Food and Drug Administration for a host of manufacturing violations at one of its plants in India, the latest instance in which the company was tagged by the regulator for quality-control problems. Reddy’s Laboratories, one of the world’s largest generic drugmakers, was cited by the U.S.

FDA 115

FDA 115

STAT

JANUARY 6, 2023

Food and Drug Administration has granted accelerated approval to the widely anticipated Alzheimer’s drug from Eisai and Biogen, a key question is the extent to which payers — private and public — will cover the treatment. Such decisions are based on myriad factors, starting with the average $26,500 price tag.

FDA 93

FDA 93

STAT

MARCH 10, 2023

By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products. But neither factor has much effect, the studies concluded.

88

88

STAT

DECEMBER 12, 2023

The news comes as researchers are still processing the Food and Drug Administration’s landmark approval of two cutting-edge sickle cell therapies, one made by Vertex Pharmaceuticals and CRISPR Therapeutics and the other by Bluebird Bio. These drugs have price tags of $2.2 million and $3.1 million, respectively.

Chemotherapy 111

Chemotherapy Immunization 111

PharmaShots

APRIL 7, 2023

TG Therapeutics Receives EMA’s CHMP Positive Opinion of Briumvi (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis Date: Apr 3, 2023 | Tags: TG Therapeutics, Briumvi, Ublituximab-xiiy, Multiple Sclerosis, Regulatory, EMA, CHMP BMS Receives EMA’s CHMP Positive Opinion of Breyanzi (lisocabtagene maraleucel) for (..)

FDA 53

FDA Immunization 53

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

STAT

OCTOBER 27, 2022

Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting treatments, one manufacturer has returned to the market — but is selling its medicine for 10 to 20 times the prices offered by the only other companies with available supplies. Continue to STAT+ to read the full story…

Dosage 101

Dosage 101

PharmaShots

JUNE 2, 2023

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734 Date: June 02, 2023 | Tags: Impact Therapeutics, Eikon Therapeutics, IMP1734, Pharma, China, Hong Kong, Macau, Taiwan BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic (..)

FDA 40

FDA 40

STAT

JANUARY 10, 2023

Food and Drug Administration for a host of serious manufacturing violations at a key plant in India, the latest instance in which the company was tagged by the regulator for quality-control problems. Sun Pharmaceutical, one of the world’s largest generic drugmakers, was scolded by the U.S.

FDA 87

FDA 87

Pharmaceutical Technology

SEPTEMBER 30, 2022

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. bluebird then broke its own pricing record when the $3m Skysona was approved, and now faces the unique challenge of selling the world's two most expensive drugs.

FDA 115

FDA Insurance 115

PharmaShots

MAY 19, 2023

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)

Medical Schools 40

Medical Schools FDA Immunization Vaccines 40

PharmaShots

JUNE 16, 2023

Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B

FDA 40

FDA Labelling 40

PharmaShots

MARCH 17, 2023

5-Adapted Bivalent Booster to Treat COVID-19 in Children ≤5 Years Date: Mar 15, 2023 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted 5-Adapted Bivalent Booster to Treat COVID-19 in Children ≤5 Years Date: Mar 15, 2023 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5-Adapted

FDA 40

FDA Labelling 40

PharmaShots

MAY 26, 2023

Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer Date: May 26, 2023 | Tags: Takeda, HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, Regulatory, Priority Review, US, FDA Gilead Receives EMA’s CHMP Positive Opinion to Extend the Use of Veklury (remdesivir) for COVID-19 Date: (..)

FDA 40

FDA 40

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

FDA 111

FDA 111

STAT

JANUARY 31, 2024

… Novo Nordisk has begun to increase availability of its blockbuster obesity drug Wegovy for new patients in the U.S. Overall, Novo saw 154% growth in obesity drug revenue in 2023, driven by sales of its older obesity drug Saxenda and the launch of Wegovy in additional countries.

82

82

PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

FDA 40

FDA 40

Pharma Tutor

JULY 13, 2022

A REVIEW ON COMPUTER AIDED DRUG DESIGN (CAAD) AND IT’S IMPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT PROCESS. Read more about A REVIEW ON COMPUTER AIDED DRUG DESIGN (CAAD) AND IT’S IMPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT PROCESS Log in or register to post comments About Authors. Sayyed , Ms. Review Articles.

59

59